GRIM‑19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade

Yan,Naimeng; Feng,Xue; Jiang,Sixiong; Sun,Weibin; Sun,Ming‑Zhong; Liu,Shuqing

doi:10.3892/ol.2020.11498

GRIM‑19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade

Authors:
- Naimeng Yan
- Xue Feng
- Sixiong Jiang
- Weibin Sun
- Ming‑Zhong Sun
- Shuqing Liu
View Affiliations

Affiliations: College of Basic Medicinal Sciences, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Urology, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116027, P.R. China
Published online on: March 31, 2020 https://doi.org/10.3892/ol.2020.11498
Pages: 4115-4121

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clear cell renal cell carcinoma (ccRCC) exhibits the highest mortality among all urological malignancies. The investigation of the potential disease progression markers can improve ccRCC diagnosis and treatment. Gene associated with retinoid‑interferon‑induced mortality‑19 (GRIM‑19) is involved in carcinogenesis and cancer progression in a variety of cancer types including RCC. While, its role in ccRCC remains unclear, this cancer type is considered the most aggressive RCC subtype. In the present study, RT‑qPCR, western blotting and immunohistochemical (IHC) assays demonstrated that GRIM‑19 protein and mRNA levels were downregulated in ccRCC tumor tissues compared with the corresponding levels noted in paracancerous non‑tumor tissues. The deficiency of this protein contributed in relaxed and/or collapsed structures of the kidney tubules and collecting duct noted in tumor tissues. Moreover, the reduction in GRIM‑19 expression was associated with high tumor, lymph nodes and metastasis (TNM) stage and Fuhrman grade of ccRCC tumors. The data suggested that GRIM‑19 acted as a tumor suppressor and that its deficiency promoted ccRCC development and progression. GRIM‑19 can be considered a potential tumor marker for ccRCC.

View Figures

View References

1	Barata PC and Rini BI: Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
2	De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N, et al: Radiotherapy for renal-cell carcinoma. Lancet Oncol. 15:e170–e177. 2014. View Article : Google Scholar : PubMed/NCBI
3	Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H and Belldegrun A: Basic research in kidney cancer. Eur Urol. 60:622–633. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ficarra V, Guillè F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, Cindolo L, Novara G, Zigeuner R, Bratti E, et al: Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer. 104:2116–2123. 2005. View Article : Google Scholar : PubMed/NCBI
5	Yan M, Zhang L, Wu Y, Gao L, Yang W, Li J, Chen Y and Jin X: Increased expression of kindlin-2 is correlated with hematogenous metastasis and poor prognosis in patients with clear cell renal cell carcinoma. FEBS Open Bio. 6:660–665. 2016. View Article : Google Scholar : PubMed/NCBI
6	Soultati A, Stares M, Swanton C, Larkin J and Turajlic S: How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? Curr Opin Urol. 25:358–366. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kalvakolanu DV: The GRIMs: A new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev. 15:169–194. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chidambaram NV, Angell JE, Ling W, Hofmann ER and Kalvakolanu DV: Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res. 20:661–665. 2000. View Article : Google Scholar : PubMed/NCBI
9	Lu H and Cao X: GRIM-19 is essential for maintenance of mitochondrial membrane potential. Mol Biol Cell. 19:1893–1902. 2008. View Article : Google Scholar : PubMed/NCBI
10	Fearnley IM, Carroll J, Shannon RJ, Runswick MJ, Walker JE and Hirst J: GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I). J Biol Chem. 276:38345–38348. 2001. View Article : Google Scholar : PubMed/NCBI
11	Fan XY, Jiang ZF, Cai L and Liu RY: Expression and clinical significance of GRIM-19 in lung cancer. Med Oncol. 29:3183–3189. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Hao H, Zhao S, Liu Q, Yuan Q, Ni S, Wang F, Liu S, Wang L and Hao A: Downregulation of GRIM-19 promotes growth and migration of human glioma cells. Cancer Sci. 102:1991–1999. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zhou Y, Li M, Wei Y, Feng D, Peng C, Weng H, Ma Y, Bao L, Nallar S, Kalakonda S, et al: Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res. 29:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
14	Angell JE, Lindner DJ, Shapiro PS, Hofmann ER and Kalvakolanu DV: Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem. 275:33416–33426. 2000. View Article : Google Scholar : PubMed/NCBI
15	Li F, Ren W, Zhao Y, Fu Z, Ji Y, Zhu Y and Qin C: Downregulation of GRIM-19 is associated with hyperactivation of p-STAT3 in hepatocellular carcinoma. Med Oncol. 29:3046–3054. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kong D, Zhao L, Du Y, He P, Zou Y, Yang L, Sun L, Wang H, Xu D, Meng X, et al: Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth. Int J Clin Exp Pathol. 7:7497–7507. 2014.PubMed/NCBI
17	Bu X, Zhao C, Wang W and Zhang N: GRIM-19 inhibits the STAT3 signaling pathway and sensitizes gastric cancer cells to radiation. Gene. 512:198–205. 2013. View Article : Google Scholar : PubMed/NCBI
18	Bezhanova SD: Tumors of the kidney. The new 2016 WHO classification of tumors of the genitourinary system. Arkh Patol. 79:48–52. 2017.(In Russian). View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Xu L and Yang W: Criteria for judging the results of immunohistochemistry. Chin Oncol. 6:31996.
21	Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X, et al: A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene. 25:7138–7147. 2006. View Article : Google Scholar : PubMed/NCBI
22	Cui L, Meng Q, Wen J, Yan Z, Gao Z, Tian Y, Xu P, Lian P and Yu H: The effect of a gene associated with retinoid-interferon-induced mortality 19 (GRIM-19) on STAT3-induced gene expression in renal carcinoma. J Biochem. 164:285–294. 2018. View Article : Google Scholar : PubMed/NCBI
23	Hao M, Shu Z, Sun H, Sun R, Wang Y, Liu T, Ji D and Cong X: GRIM-19 expression is a potent prognostic marker in colorectal cancer. Hum Pathol. 46:1815–1820. 2015. View Article : Google Scholar : PubMed/NCBI
24	Shao YP, Cheng XD and Wan XY: Expression and clinical significance of GRIM-19 in epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi. 47:751–755. 2012.(In Chinese). PubMed/NCBI
25	Zhou T, Chao L, Rong G, Wang C, Ma R and Wang X: Down-regulation of GRIM-19 is associated with STAT3 overexpression in breast carcinomas. Hum Pathol. 44:1773–1779. 2013. View Article : Google Scholar : PubMed/NCBI